TITLE

Oncology

AUTHOR(S)
Pines, Noah
PUB. DATE
October 2011
SOURCE
Medical Marketing & Media;Oct2011, Vol. 46 Issue 10, p38
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers information on pharmaceutical company's focus on targeted therapies for the treatment of cancer. Analyst Tim Anderson of Sanford Bernstein says that molecular understanding and targeted therapeutics is unique to oncology. It also include a table that lists the top 50 oncology products in 2010 including Avastin from Genentech Inc./Roche, Gleevec from Novartis AG, and Taxotere from Sanofi-Aventis SA.
ACCESSION #
66879472

 

Related Articles

  • Oncology. Noah Pines // Medical Marketing & Media;Sep2012, Vol. 47 Issue 9, p46 

    The article discusses the oncology medicine launches from the newly approved drugs for cancer. It notes that marketing executive Alexander Hardy at Roche/Genentech reveals that every medicine in development has a corresponding biomarker program. It explores the top chemotherapy and targeted...

  • Pharmaceutical Company Round-Up.  // PharmaWatch: Monthly Review;Feb2010, Vol. 9 Issue 2, p3 

    The article presents updates related to the condition of pharmaceutical companies in the U.S. Datamonitor Ltd. projects that Sanofi-Aventis SA will retain its leading position in the insomnia market owing to the success of its Ambien drug. Novartis AG has launched its Fanapt for the treatment of...

  • Cancer News Round-up.  // PharmaWatch: Cancer;Mar2005, Vol. 4 Issue 3, p2 

    The article reports on the developments for cancer treatments made by several pharmaceutical companies. Genentech Inc. indicated that its Avastin therapeutic had increased the survival of patients having colorectal cancer. Sanofi-Aventis had gained an approval from the U.S. Food and Drug...

  • Pharmaceuticals Industry Profile: Italy.  // Pharmaceuticals Industry Profile: Italy;Dec2006, p1 

    Presents a profile of the Pharmaceuticals industry in Italy. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pharmaceuticals Industry Profile: Russia.  // Pharmaceuticals Industry Profile: Russia;Dec2010, p1 

    Presents a profile of the Pharmaceuticals industry in Russia. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Generics Industry Profile: United Kingdom.  // Generics Industry Profile: United Kingdom;May2010, p1 

    Presents a profile of the Generics industry in the United Kingdom. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Generics Industry Profile: United Kingdom.  // Generics Industry Profile: United Kingdom;Jul2010, p1 

    Presents a profile of the Generics industry in the United Kingdom. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • The year of the blockbuster.  // Pharmaceutical Representative;Apr2007, Vol. 37 Issue 4, p11 

    The article provides updates for the U.S. pharmaceutical industry in 2007, as forecasted by IMS Health Inc. One highlight is the launching of seven potential blockbuster drugs, which include the hypertension treatment Tekturna by Novartis Corp., weight-loss drug Acomplia by Sanofi-Aventis SA,...

  • Quartlery Reports.  // Contract Pharma;Mar2012, Vol. 14 Issue 2, p133 

    The article reports on the financial performances of several pharmaceutical companies for the fiscal year 2011, particularly the fourth quarter. It notes that Pfizer Inc. has posted a total of 16.7 billion dollars, with emphasis on the 5.4% revenue in primary care products. It adds that Novartis...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics